AIM ImmunoTech is trading 7.32% up at $0.24, with no clear company-specific catalyst identified for the August 17 pre-market move.

  • The company closed August 14, 2026, at $0.22.
  • Latest notable developments were the August 10 second-quarter report and August 3 completion of final dosing in the DURIPANC trial; both predated this move.
  • Broader sentiment was modestly positive, with Nasdaq futures up 0.55%, but that does not establish causation.